Skip to main content
. 2022 Jun 2;12:858523. doi: 10.3389/fonc.2022.858523

Table 2.

Baseline characteristics of all patients with CLL and those in the IGH-t (IGH-BCL2, IGH-BCL3, IGH-others) and non-IGH-t groups.

All patients (n=138) IGH-t (n=25) non-IGH-t (n=113) IGH-t vsnon-IGH-t (P-value)
IGH-BCL2 (n=10) IGH-BCL3(n=3) IGH-others (n=12)
Median age (range, years) 61 (27–84) 61 (46–77) 54 (46–56) 62 (40–75) 61 (27–84) 0.619
Male 96 8 3 9 76 0.311
Rai stage 0.198
0–II 64 7 1 7 49
III–IV 74 3 2 5 64
Binet stage 0.690
A 43 5 0 3 35
B 36 3 2 3 28
C 59 2 1 6 50
Elevated β2 MG 37 2 2 4 29 0.691
Flow score 0.032
3 37 1 2 8 26
≥4 101 9 1 4 87
Unmutated-IGHV 29 0 3 2 24 0.362
IGHV-ND 35 1 0 0 34
CK 22 0 2 3 17 0.540

CLL, Chronic lymphocytic lymphoma; IGH, immunoglobulin heavy chain gene; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy variable; g2 MG, β2-microglobulin; ND, data not done; CK, complex karyotype.